PT1411916E - Métodos e materiais para o tratamento de deficiência em testosterona nos homens - Google Patents

Métodos e materiais para o tratamento de deficiência em testosterona nos homens Download PDF

Info

Publication number
PT1411916E
PT1411916E PT02748104T PT02748104T PT1411916E PT 1411916 E PT1411916 E PT 1411916E PT 02748104 T PT02748104 T PT 02748104T PT 02748104 T PT02748104 T PT 02748104T PT 1411916 E PT1411916 E PT 1411916E
Authority
PT
Portugal
Prior art keywords
methods
men
treatment
materials
testosterone deficiency
Prior art date
Application number
PT02748104T
Other languages
English (en)
Inventor
Joseph S Podolski
Original Assignee
Repros Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23175972&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT1411916(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Repros Therapeutics Inc filed Critical Repros Therapeutics Inc
Publication of PT1411916E publication Critical patent/PT1411916E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Beans For Foods Or Fodder (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PT02748104T 2001-07-09 2002-07-09 Métodos e materiais para o tratamento de deficiência em testosterona nos homens PT1411916E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US30431301P 2001-07-09 2001-07-09

Publications (1)

Publication Number Publication Date
PT1411916E true PT1411916E (pt) 2008-12-10

Family

ID=23175972

Family Applications (1)

Application Number Title Priority Date Filing Date
PT02748104T PT1411916E (pt) 2001-07-09 2002-07-09 Métodos e materiais para o tratamento de deficiência em testosterona nos homens

Country Status (24)

Country Link
US (6) US7759360B2 (pt)
EP (1) EP1411916B1 (pt)
JP (2) JP4845165B2 (pt)
KR (1) KR100851648B1 (pt)
CN (2) CN1289075C (pt)
AT (1) ATE406153T1 (pt)
AU (1) AU2002318225B2 (pt)
BR (1) BR0211067A (pt)
CA (2) CA2453337C (pt)
CL (1) CL2004000026A1 (pt)
CO (1) CO5550428A2 (pt)
CY (1) CY1108563T1 (pt)
DE (1) DE60228583D1 (pt)
DK (1) DK1411916T3 (pt)
EC (1) ECSP044937A (pt)
ES (1) ES2312593T3 (pt)
HK (1) HK1071521A1 (pt)
MX (1) MXPA04000097A (pt)
NZ (2) NZ551013A (pt)
PL (1) PL211339B1 (pt)
PT (1) PT1411916E (pt)
RU (1) RU2297218C2 (pt)
WO (1) WO2003005954A2 (pt)
ZA (1) ZA200400142B (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7173064B2 (en) 2001-07-09 2007-02-06 Repros Therapeutics Inc. Methods and compositions with trans-clomiphene for treating wasting and lipodystrophy
US7737185B2 (en) * 2001-07-09 2010-06-15 Repros Therapeutics Inc. Methods and compositions with trans-clomiphene
PT1411916E (pt) 2001-07-09 2008-12-10 Repros Therapeutics Inc Métodos e materiais para o tratamento de deficiência em testosterona nos homens
MX2007000050A (es) * 2004-07-14 2007-07-10 Repros Therapeutics Inc Trans-clomifeno para el tratamiento de hipertrofia de prostata benigna, cancer de prostata, hipogonadismo, trigliceridos elevados y colesterol elevado.
KR20070100811A (ko) * 2005-02-04 2007-10-11 레프로스 쎄라피우틱스 아이엔씨. 남성불임의 치료를 위한 트랜스―클로미펜을 이용한 물질과치료방법
PL383444A1 (pl) * 2005-03-22 2008-03-17 Repros Therapeutics Inc. Sposoby dawkowania trans-klomifenu
WO2008157335A2 (en) * 2007-06-13 2008-12-24 Quatrx Pharmaceuticals Company Methods for the treatment of erectile dysfunction using fispemifene
US20090105348A1 (en) * 2007-10-18 2009-04-23 Harry Fisch Treatment of migraine headaches using antiestrogens
US20110118355A1 (en) * 2007-09-21 2011-05-19 Harry Fisch Treatment of migraine headaches using antiestrogens
ES2718912T3 (es) * 2007-10-16 2019-07-05 Repros Therapeutics Inc Trans-clomifeno para el tratamiento de la diabetes en hombres hipogonadales
US20090215738A1 (en) * 2008-02-26 2009-08-27 Michael Charles Scally Prevention and treatment of an increase in cardiovascular risk, adverse cardiovascular events, infertility, and adverse psychological effects after androgen or gnrh analogue intake
TWI477276B (zh) 2008-04-28 2015-03-21 Repros Therapeutics Inc 抗黃體素給藥方案
RU2474424C2 (ru) * 2010-09-24 2013-02-10 Государственное образовательное учреждение высшего профессионального образования "Ивановская государственная медицинская академия Федерального агентства по здравоохранению и социальному развитию" Способ коррекции гиперэстрадиолемии и нормогонадотропного гипогонадизма у мужчин
UA113291C2 (xx) 2011-08-04 2017-01-10 Метаболіти транскломіфену і їх застосування
US20140235601A1 (en) * 2011-08-09 2014-08-21 Kenneth W. Adams Use of Aromatase Inhibitor Or Estrogen Blocker For Increasing Spermatogenesis Or Testosterone Levels In Males
SG10201704858PA (en) 2012-05-31 2017-07-28 Repros Therapeutics Inc Formulations and methods for vaginal delivery of antiprogestins
IN2015DN01698A (pt) * 2012-08-21 2015-07-03 Repros Therapeutics Inc
CN104994877A (zh) 2012-11-02 2015-10-21 利普生物药剂公司 用于癌症治疗的反式-克罗米芬
MX2015004821A (es) 2012-11-02 2015-08-14 Repros Therapeutics Inc Metodos y composiciones para tratar condiciones dependientes de la progesterona.
US9814687B2 (en) * 2014-08-20 2017-11-14 Professional Compounding Centers Of America Transdermal pharmaceutical compositions including C-SERMs for low testosterone levels in men
RU2586305C1 (ru) * 2015-02-02 2016-06-10 Государственное бюджетное образовательное учреждение высшего профессионального образования "Ивановская государственная медицинская академия" Министерства здравоохранения Российской Федерации Способ лечения обструктивной азооспермии и криптозооспермии у пациентов с хроническим простатитом
WO2017182097A1 (en) 2016-04-22 2017-10-26 F.I.S. - Fabbrica Italiana Sintetici S.P.A. Process for the preparation of enclomiphene citrate having needle shaped crystal habit.

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2914563A (en) 1957-08-06 1959-11-24 Wm S Merrell Co Therapeutic composition
IT951631B (it) 1971-03-18 1973-07-10 Richardson Merrell Spa Composti utili per la separazione di isomeri ottici geometrici e strutturali e relativo procedimen to di sintesi
US4061733A (en) * 1976-10-15 1977-12-06 Narayan Vishwanath Gunjikar Veterinary compositions for inducing estrus in animals and method
US4729999A (en) 1984-10-12 1988-03-08 Bcm Technologies Antiestrogen therapy for symptoms of estrogen deficiency
DE3660489D1 (en) 1985-06-08 1988-09-15 Asta Pharma Ag Derivatives of 1,1,2,2-tetramethyl-1,2-bis(2-fluoro-4-hydroxyphenyl) ethane
US4820736A (en) * 1987-03-20 1989-04-11 Yale University Use of clomiphene to predict fertility in a human female
GB8926171D0 (en) * 1989-11-20 1990-01-10 Applied Research Systems Treatment of infertility
JPH04312522A (ja) 1991-04-08 1992-11-04 Yoshiaki Kawashima 徐放性錠剤の製造方法
US5681585A (en) * 1991-12-24 1997-10-28 Euro-Celtique, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5580578A (en) * 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5776923A (en) * 1993-01-19 1998-07-07 Endorecherche, Inc. Method of treating or preventing osteoporosis by adminstering dehydropiandrosterone
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
US5650425A (en) * 1994-04-04 1997-07-22 Pharmos Corporation Permanently ionic derivatives of steroid hormones and their antagonists
CA2192708A1 (en) 1994-06-17 1995-12-28 Kenneth J. Himmelstein In situ gel-forming delivery vehicle for bio-affecting substances, and method of use
DE4435368A1 (de) * 1994-09-22 1996-03-28 Schering Ag Verwendung von Aromatasehemmern zur Herstellung eines Arzneimittels zur Behandlung eines relativen Androgenmangels beim Mann
EP0844870B1 (en) * 1995-08-17 2001-11-21 Csir Controlled release products
US5773031A (en) * 1996-02-27 1998-06-30 L. Perrigo Company Acetaminophen sustained-release formulation
IL120262A (en) * 1996-02-28 2001-01-28 Pfizer Droloxifene and derivatives thereof for use in increasing serum testosterone levels
ATE277739T1 (de) * 1996-10-28 2004-10-15 Gen Mills Inc Einbettung und einkapselung von teilchen zur kontrollierten abgabe
BR9809064A (pt) * 1997-04-03 2002-01-02 Guilford Pharm Inc Polìmeros biodegradáveis de poliéster de tereftalato-polifosfato, composições, artigos e métodos para fazer e usar os mesmos
US6653297B1 (en) * 1997-07-03 2003-11-25 Medical College Of Hampton Roads Control of selective estrogen receptor modulators
US6342250B1 (en) * 1997-09-25 2002-01-29 Gel-Del Technologies, Inc. Drug delivery devices comprising biodegradable protein for the controlled release of pharmacologically active agents and method of making the drug delivery devices
US6413533B1 (en) 1998-05-07 2002-07-02 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
WO2000007996A2 (en) * 1998-08-07 2000-02-17 Chiron Corporation Pyrazoles as estrogen receptor modulators
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
PE20010404A1 (es) * 1999-06-11 2001-04-09 Watson Pharmaceuticals Inc Combinacion de esteroides androgenicos no orales y compuestos estrogenicos y su uso en mujeres
CA2321321A1 (en) * 1999-09-30 2001-03-30 Isotis B.V. Polymers loaded with bioactive agents
US6258802B1 (en) 1999-10-06 2001-07-10 Medical College Of Hampton Roads Corticoid therapy
AU3104301A (en) * 2000-01-20 2001-07-31 Noven Pharmaceuticals, Inc. Compositions and methods to effect the release profile in the transdermal administration of active agents
US7067557B2 (en) * 2000-05-26 2006-06-27 Harry Fisch Methods of treating androgen deficiency in men using selective antiestrogens
WO2001091744A1 (en) 2000-05-26 2001-12-06 Harry Fisch Methods of treating androgen deficiency in men using selective antiestrogens
PT1318837E (pt) 2000-08-11 2004-12-31 Wyeth Corp Metodo de tratamenton de carcinoma positivo a receptor de estrogenio
US6503894B1 (en) * 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
US20040192598A1 (en) 2000-10-11 2004-09-30 Laura Kragie Composition and method of alleviating adverse side effects and/or enhancing efficacy of agents that inhibit aromatase
WO2002055020A2 (en) * 2000-12-11 2002-07-18 Testocreme Llc Topical testosterone formulations and associated methods
PT1411916E (pt) 2001-07-09 2008-12-10 Repros Therapeutics Inc Métodos e materiais para o tratamento de deficiência em testosterona nos homens
US7173064B2 (en) * 2001-07-09 2007-02-06 Repros Therapeutics Inc. Methods and compositions with trans-clomiphene for treating wasting and lipodystrophy
US6645974B2 (en) * 2001-07-31 2003-11-11 Merck & Co., Inc. Androgen receptor modulators and methods for use thereof
WO2003026568A2 (en) 2001-09-21 2003-04-03 Merck & Co., Inc. Androstanes as androgen receptor modulators
US6600110B1 (en) * 2001-10-01 2003-07-29 Gram Precision Portable digital readout scale
US20060269611A1 (en) * 2001-11-29 2006-11-30 Steiner Mitchell S Prevention and treatment of androgen-deprivation induced osteoporosis
US7105679B2 (en) * 2001-12-19 2006-09-12 Kanojia Ramesh M Heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators
JP4312522B2 (ja) 2003-06-30 2009-08-12 株式会社リコー 現像剤補給方法、現像剤補給装置、及び、画像形成装置
MX2007000050A (es) 2004-07-14 2007-07-10 Repros Therapeutics Inc Trans-clomifeno para el tratamiento de hipertrofia de prostata benigna, cancer de prostata, hipogonadismo, trigliceridos elevados y colesterol elevado.
KR20070100811A (ko) 2005-02-04 2007-10-11 레프로스 쎄라피우틱스 아이엔씨. 남성불임의 치료를 위한 트랜스―클로미펜을 이용한 물질과치료방법
JP2008537538A (ja) 2005-02-11 2008-09-18 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｖｅｇｆ拮抗剤及び降圧剤の治療的組み合わせ
PL383444A1 (pl) 2005-03-22 2008-03-17 Repros Therapeutics Inc. Sposoby dawkowania trans-klomifenu
KR20080035675A (ko) 2005-08-05 2008-04-23 레프로스 쎄라피우틱스 아이엔씨. 클로미펜을 이용하여 여성의 불임을 치료하는 방법들과조성물들
EP1829534A1 (en) 2006-03-02 2007-09-05 Laboratorios Del Dr. Esteve, S.A. Use of compounds binding to the sigma receptor for the treatment of metabolic syndrome
ES2718912T3 (es) 2007-10-16 2019-07-05 Repros Therapeutics Inc Trans-clomifeno para el tratamiento de la diabetes en hombres hipogonadales
US20100111901A1 (en) 2008-11-03 2010-05-06 Auspex Pharmaceuticals, Inc. Triazole inhibitors of aromatase
TW201500041A (zh) 2008-11-07 2015-01-01 Repros Therapeutics Inc 用於代謝症候群與第２型糖尿病的反式氯米芬
US20100144687A1 (en) 2008-12-05 2010-06-10 Glaser Rebecca L Pharmaceutical compositions containing testosterone and an aromatase inhibitor
US20140235601A1 (en) 2011-08-09 2014-08-21 Kenneth W. Adams Use of Aromatase Inhibitor Or Estrogen Blocker For Increasing Spermatogenesis Or Testosterone Levels In Males

Also Published As

Publication number Publication date
US10561624B2 (en) 2020-02-18
RU2004100535A (ru) 2005-06-10
NZ530491A (en) 2007-08-31
ZA200400142B (en) 2006-02-22
NZ551013A (en) 2008-04-30
WO2003005954B1 (en) 2003-12-04
US20040097597A1 (en) 2004-05-20
CN1551765A (zh) 2004-12-01
CN1954807A (zh) 2007-05-02
WO2003005954A2 (en) 2003-01-23
PL374121A1 (en) 2005-10-03
MXPA04000097A (es) 2004-05-21
JP2009280623A (ja) 2009-12-03
US7759360B2 (en) 2010-07-20
EP1411916A4 (en) 2005-08-17
EP1411916A2 (en) 2004-04-28
US8618176B2 (en) 2013-12-31
WO2003005954A3 (en) 2003-10-23
CA2453337A1 (en) 2003-01-23
US20150265553A1 (en) 2015-09-24
CL2004000026A1 (es) 2005-02-04
US7368480B2 (en) 2008-05-06
AU2002318225B2 (en) 2007-12-13
DK1411916T3 (da) 2008-12-15
BR0211067A (pt) 2006-10-31
CO5550428A2 (es) 2005-08-31
KR100851648B1 (ko) 2008-08-13
ES2312593T3 (es) 2009-03-01
US20160354325A1 (en) 2016-12-08
CA2777199A1 (en) 2003-01-23
US20040241224A1 (en) 2004-12-02
US20140093560A1 (en) 2014-04-03
JP4845165B2 (ja) 2011-12-28
US20100286281A1 (en) 2010-11-11
EP1411916B1 (en) 2008-08-27
ATE406153T1 (de) 2008-09-15
PL211339B1 (pl) 2012-05-31
ECSP044937A (es) 2004-04-28
DE60228583D1 (de) 2008-10-09
CY1108563T1 (el) 2014-04-09
JP2005520779A (ja) 2005-07-14
CN1289075C (zh) 2006-12-13
RU2297218C2 (ru) 2007-04-20
HK1071521A1 (en) 2005-07-22
KR20040013131A (ko) 2004-02-11
CA2453337C (en) 2012-08-28

Similar Documents

Publication Publication Date Title
PL374121A1 (en) Methods and materials for the treatment of testosterone deficiency in men
MXPA03001645A (es) Composiciones y metodos para el diagnostico y tratamiento de tumores.
MXPA04002593A (es) Composiciones y metodos para el diagnostico y tratamiento de tumor.
MXPA03011985A (es) Composiciones y metodos para el diagnostico y tratamiento de tumores.
TW200501960A (en) Synergistic kits and compositions for treating cancer
WO2006068729A3 (en) Methods and compositions for enhancing iron absorption
AU6147401A (en) Compositions and methods for the treatment of cancer
WO2006110760A3 (en) Compositions and methods for the diagnosis and treatment of tumor
WO2002016581A3 (en) Compositions and methods for the diagnosis and treatment of tumor
MXPA03001643A (es) Composiciones y metodos para el diagnostico y tratamiento de tumores.
CA2418167A1 (en) Compositions and methods of preventing or reducing the risk or incidence of skeletal injuries in horses
IL157457A0 (en) Benzimidazoles that are useful in treating sexual dysfuction
SI1546182T1 (sl) Sestavki in postopki za diagnozo in zdravljenje tumorja
CA2408541A1 (en) Treating eczema and/or psoriasis
WO2004009029A3 (en) Compositions and methods for treating and preventing infection
EP1303300A4 (en) COMPOSITIONS AND METHODS FOR TREATING CANDIDIASIS
IL154354A0 (en) Composition for prophylaxis and treatment of cancer
DE60108359D1 (de) Biologisch wirksame, analoge verbindungen von discodermoliden
DE60109594D1 (de) R-eliprodil zur behandlung von glaucoma
MXPA03002494A (es) Metodo para reducir toxicidad de quimio terapias combinadas.
MXPA05008293A (es) Composiciones y metodos para el diagnostico y tratamiento de tumores.
ATE251460T1 (de) Verwendung von danazol zur behandlung von hypogonadismus in männern
ATE321528T1 (de) Verwendung von dattelkern-extrakt zur minderung der anzeichen der hautalterung
WO2003053334A3 (en) Compositions and methods for the diagnosis and treatment of tumor
ECSP982362A (es) Compuestos de quinolina y quinazolina utiles en terapia